title: Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.
abstract: Bladder and renal cancer are two representative cases of tumors that respond differentially to gemcitabine. Previous studies have shown that gemcitabine can trigger apoptosis in various cancer cells. Herein, we sought to investigate the impact of gemcitabine on the expression levels of the BCL2 family members BCL2, BAX, and BCL2L12 and the apoptosis-related microRNAs miR-182, miR-96, miR-145, and miR-16 in the human bladder and kidney cancer cell lines T24 and Caki-1, respectively. Cancer cells' viability as well as the IC50 doses of gemcitabine were estimated by the MTT assay, while the detection of cleaved PARP via Western blotting was used as an indicator of apoptosis. Furthermore, T24 and Caki-1 cells' ability to recover from treatment was also monitored. Two different highly sensitive quantitative real-time RT-PCR methodologies were developed in order to assess the expression levels of BCL2 family genes and microRNAs. Exposure of cancer cells to gemcitabine produced the IC50 values of 30 and 3 nM for Caki-1 and T24 cells, correspondingly, while cleaved PARP was detected only in Caki-1 cells. T24 cells demonstrated the ability to recover from gemcitabine treatment, whereas Caki-1 cells' recovery capability was dependent on the initial time of exposure. BCL2 and BAX were significantly modulated in treated Caki-1 cells. Instead, T24 cells exhibited alterations only in the latter, as well as in all studied microRNAs. Therefore, according to our data, bladder and renal cancer cells' response to gemcitabine is accompanied by distinct alterations in the expression levels of their apoptosis-related genes and microRNAs.
authors.affiliation: Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimiopolis, Athens, 15701, Greece.
authors.forename: Emmanuel I
authors.initials: EI
authors.lastname: Papadopoulos
authors.forename: George M
authors.initials: GM
authors.lastname: Yousef
authors.forename: Andreas
authors.initials: A
authors.lastname: Scorilas
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000378:metabolism; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000378:metabolism; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D035683:MicroRNAs; D019253:Proto-Oncogene Proteins c-bcl-2; D012333:RNA, Messenger; D003841:Deoxycytidine; D000093542:Gemcitabine
references.citation: Science. 1997 Feb 21;275(5303):1129-32
references.pmid: 9027314
references.citation: Nature. 1970 Aug 15;227(5259):680-5
references.pmid: 5432063
references.citation: J Cell Sci. 2001 Oct;114(Pt 20):3771-8
references.pmid: 11707529
references.citation: Tumour Biol. 2012 Jun;33(3):865-75
references.pmid: 22238053
references.citation: J Urol. 2012 Sep;188(3):707-15
references.pmid: 22818130
references.citation: Urol Int. 2002;69(1):46-50
references.pmid: 12119439
references.citation: Cancer Chemother Pharmacol. 1996;37(5):491-5
references.pmid: 8599874
references.citation: Int J Cancer. 2009 Feb 1;124(3):511-5
references.pmid: 19003982
references.citation: Exp Biol Med (Maywood). 2010 Jul;235(7):814-24
references.pmid: 20558835
references.citation: PLoS One. 2012;7(11):e51056
references.pmid: 23226455
references.citation: Cancer Res. 2000 Dec 15;60(24):7133-41
references.pmid: 11156422
references.citation: Asian Pac J Cancer Prev. 2010;11(4):905-11
references.pmid: 21133599
references.citation: Drug Resist Updat. 2010 Jun;13(3):57-66
references.pmid: 20236855
references.citation: Genomics. 2001 Mar 1;72(2):217-21
references.pmid: 11401436
references.citation: Int J Cancer. 2008 Jul 15;123(2):372-379
references.pmid: 18449891
references.citation: Eur J Surg Oncol. 2009 Oct;35(10):1119-23
references.pmid: 19443172
references.citation: Nat Protoc. 2008;3(6):1101-8
references.pmid: 18546601
references.citation: Br J Cancer. 2001 Jan 5;84(1):100-5
references.pmid: 11139321
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Semin Oncol. 1995 Aug;22(4 Suppl 11):19-25
references.pmid: 7481840
references.citation: J Immunol Methods. 1982 Dec 30;55(3):297-307
references.pmid: 6820029
references.citation: J Cell Physiol. 2010 May;223(2):289-98
references.pmid: 20112282
references.citation: Oncol Lett. 2012 Sep;4(3):561-565
references.pmid: 23741253
references.citation: Urol Res. 1995;23(5):293-300
references.pmid: 8839385
references.citation: Oncogene. 2010 Feb 18;29(7):1073-84
references.pmid: 19915607
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3207-12
references.pmid: 19202062
references.citation: Clin Pharmacol Ther. 2013 Jan;93(1):98-104
references.pmid: 23212103
references.citation: Ann Oncol. 2006 May;17 Suppl 5:v7-12
references.pmid: 16807468
references.citation: Cell Death Differ. 2001 Jun;8(6):588-94
references.pmid: 11536009
references.citation: Ann Oncol. 1993 Apr;4(4):331-2
references.pmid: 8518225
references.citation: Proc Natl Acad Sci U S A. 1984 Nov;81(22):7166-70
references.pmid: 6334305
references.citation: Am J Transl Res. 2010 Mar 25;2(2):170-80
references.pmid: 20407606
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: J Gastrointest Surg. 2004 Dec;8(8):1072-8
references.pmid: 15585396
references.citation: Cancer Lett. 2006 Jun 8;237(1):56-66
references.pmid: 16009487
references.citation: Curr Opin Oncol. 2008 Jan;20(1):97-103
references.pmid: 18043263
references.citation: Eur Urol. 2011 Oct;60(4):615-21
references.pmid: 21741761
references.citation: Anticancer Res. 2001 Sep-Oct;21(5):3161-6
references.pmid: 11848468
references.citation: J Hematol Oncol. 2011 Sep 09;4:35
references.pmid: 21906310
references.citation: Toxicol Pathol. 2007 Jun;35(4):495-516
references.pmid: 17562483
references.citation: Anal Biochem. 1976 May 7;72:248-54
references.pmid: 942051
references.citation: Biotechniques. 2005 Oct;39(4):519-25
references.pmid: 16235564
references.citation: Cell Death Differ. 2012 Jan;19(1):107-20
references.pmid: 21760595
references.citation: Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
references.pmid: 16166262
references.citation: Cell. 2009 Jan 23;136(2):215-33
references.pmid: 19167326
references.citation: Ann N Y Acad Sci. 2007 Jan;1095:35-44
references.pmid: 17404015
references.citation: Gene. 2012 Aug 15;505(1):153-66
references.pmid: 22664385
references.citation: Exp Cell Res. 2001 Oct 1;269(2):193-201
references.pmid: 11570811
references.citation: Mol Med Rep. 2012 Jan;5(1):260-5
references.pmid: 21993544
references.citation: Cell. 1993 Aug 27;74(4):609-19
references.pmid: 8358790
references.citation: Crit Rev Clin Lab Sci. 2006;43(1):1-67
references.pmid: 16531274
references.citation: Nucleic Acids Res. 2011 Jan;39(Database issue):D152-7
references.pmid: 21037258